Halozyme Therapeutics, Inc.  

(Public, NASDAQ:HALO)   Watch this stock  
Find more results for halo
+0.44 (4.88%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.16 - 10.00
52 week 6.88 - 18.18
Open 9.19
Vol / Avg. 5.50M/1.23M
Mkt cap 1.19B
P/E     -
Div/yield     -
EPS -0.71
Shares 125.39M
Beta 1.65
Inst. own 72%
Feb 25, 2015
Q4 2014 Halozyme Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
Halozyme Therapeutics Inc at Oppenheimer Healthcare Conference
Dec 3, 2014
Halozyme Therapeutics Inc at Piper Jaffray Healthcare Conference
Nov 12, 2014
Halozyme Therapeutics Inc at Credit Suisse Healthcare Conference
Nov 10, 2014
Q3 2014 Halozyme Therapeutics Inc Earnings Call
Nov 10, 2014
Q3 2014 Halozyme Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -138.85% -152.33%
Operating margin -130.26% -146.78%
EBITD margin - -144.54%
Return on average assets -46.93% -70.59%
Return on average equity -170.82% -578.43%
Employees 170 -
CDP Score - -


11388 Sorrento Valley Road
United States - Map
+1-858-7948889 (Phone)
+1-858-7048311 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company�s research focuses primarily on human enzymes that alter the extracellular matrix. The Company�s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon Corporation (Intrexon), with three product candidates.

Officers and directors

Kenneth J. Kelley Ph.D. Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Helen I. Torley President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
David A. Ramsay CPA Chief Financial Officer, Vice President
Age: 49
Bio & Compensation  - Reuters
H. Michael Shepard Ph.D. Vice President, Chief Scientific Officer
Age: 63
Bio & Compensation  - Reuters
Matthew L. Posard Director
Age: 47
Bio & Compensation  - Reuters
Robert L. Engler M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 53
Bio & Compensation  - Reuters
Randal J. Kirk Independent Director
Age: 60
Bio & Compensation  - Reuters
Connie L. Matsui Independent Director
Age: 60
Bio & Compensation  - Reuters